울혈성 심부전 치료 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 지역별, 부문별 예측(2025-2030년)

Congestive Heart Failure Treatment Devices Market Size, Share & Trends Analysis Report By Product (Ventricular Assist Devices, Implantable Cardioverter Defibrillators, Counter Pulsation Devices, Pacemakers), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,443,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,862,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,700,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

울혈성 심부전 치료 기기 시장 성장 및 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 울혈성 심부전 치료 기기 시장 규모는 2030년 82억 달러에 달할 것으로 예상되며, 2025-2030년 동안 CAGR 6.7%로 성장할 것으로 예상됩니다. 성장의 주요 요인 중 하나입니다. 좌식 생활 습관, 정신적 스트레스, 정크 푸드 소비 경향은 CVDs 개발의 주요 요인입니다.

미국 메디케어 제도와 같은 유리한 상환 정책은 이 산업의 주요 성장 요인으로 여겨지고 있습니다. 현재 각 업체들은 CHF 치료에 사용되는 보조 인공심장(VAD), 이식형 제세동기(ICD), 심박조율기(Pacemaker)와 같은 장치에 대해 환자들에게 혜택이 돌아갈 수 있는 신제품 플랫폼을 제공하고 있습니다.

업계 관계자들은 개인화된 치료를 제공할 수 있는 실용적인 제품을 개발하기 위해 노력하고 있습니다. 이러한 발전은 정확도를 높이고, 워크플로우를 강화하며, 오류 발생률을 줄이기 위한 추가 기능을 제공하고 있습니다.

울혈성 심부전 치료 기기 시장 보고서 하이라이트

• 제품별 시장은 보조 인공심장, 카운터펄세이션 장치, ICD, 심박조율기, 심장 재동기화 장치로 구분됩니다. 경정맥형과 피하형 두 가지 유형으로 구성된 ICD 부문이 2024년에 유리한 점유율을 차지했으며, 심박조율기 부문이 그 뒤를 이었습니다. 이는 제세동기와 심박조율기가 심부전 치료의 최전선에 있기 때문입니다.
• 한편, 보조 인공심장(VAD) 부문은 보험 환급 범위와 보조 인공심장의 기술 발전으로 인해 예측 기간 동안 큰 성장을 보일 것으로 예상됩니다.
• 보조 인공심장은 이식 부위에 따라 좌심실 보조 인공심장(LVAD)과 우심실 보조 인공심장(RVAD)으로 구분되며, LVAD와 RVAD를 함께 이식하는 경우 양심실보조장치(BIVAD)라고 합니다.
• 북미 울혈성 심부전 치료 기기 시장은 2024년 45.6%의 점유율로 세계 시장을 장악했습니다. 이는 CVD를 앓고 있는 인구 기반이 크고, 노인 인구가 많기 때문으로 분석됩니다.
• 시장 진입 기업들은 시장에서의 지위를 유지하기 위해 현재 제품 포트폴리오를 개선하기 위해 적극적으로 노력하고 있습니다. 또한, 시장 개척과 미개척 국가로의 시장 진출이 시장 성장을 촉진할 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 울혈성 심부전 치료 기기 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 울혈성 심부전 치료 기기 시장 분석 툴
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 울혈성 심부전 치료 기기 시장 : 제품별, 추정·동향 분석

• 세계의 울혈성 심부전 치료 기기 시장 : 제품 대시보드
• 세계의 울혈성 심부전 치료 기기 시장 : 제품 변동 분석
• 울혈성 심부전 치료 기기 세계 시장(제품별, 매출별)
• 보조 인공 심장(VAD)
  • LVAD
  • RVAD
  • BiVAD
• 역박동 기기
• 이식형 제세동기
  • 경정맥 ICD
  • 피하 ICD
• 페이스메이커
  • 이식형
  • 외장형
• 심장재동기화치료
  • 심장재동기화치료 제세동기(CRT-D)
  • 심장재동기화치료 페이스메이커(CRT-P)

제5장 울혈성 심부전 치료 기기 시장 : 지역별, 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제6장 경쟁 구도

• 기업/경쟁 분류
• 벤더 상황
  • 주요 기업의 시장 점유율 분석, 2024년
  • Jarvik Heart Inc.
  • ReliantHeart, Inc.
  • BIoTronik SE &Co. KG
  • Berlin Heart GmbH
  • Abbott
  • Medtronic
  • Boston Scientific Corporation
  • Teleflex, Inc.

ksm

영문 목차

영문목차

Congestive Heart Failure Treatment Devices Market Growth & Trends:

The global congestive heart failure treatment devices market size is expected to reach USD 8.2 billion in 2030 and is projected to grow at a CAGR of 6.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising burden of CVDs is one of the prime factors responsible for lucrative growth of this vertical. Sedentary lifestyles, mental stress, and junk food consumption tendencies are the key factors responsible for development of CVDs.

Favorable reimbursement policies, such as the U.S. Medicare system, are observed to be a prime growth factor for this industry. Companies now provide new product platforms, which have reimbursement coverage that benefit the patient. The reimbursement can be availed for devices, such as Ventricular Assist Devices (VADs), Implantable Cardiovascular Defibrillators (ICDs), and pacemakers, which are used to treat CHF.

The industry participants are more focused on developing high-utility products, which can deliver personalized care. These advancements are improving the accuracy and provide additional capabilities to enhance the workflow and reduce the incidence of errors.

Congestive Heart Failure Treatment Devices Market Report Highlights:

• The market by product is segmented into VADs, Counter Pulsation Devices, ICDs, pacemakers, and cardiac resynchronization devices. The ICD segment consisting of two types, transvenous and subcutaneous, held a lucrative share in 2024, which was followed by the pacemaker's segment. This can be attributed to the fact that defibrillators and pacemakers form the primary line of treatment administered for heart failure.
• On the other hand, the VAD segment is anticipated to grow at a significant rate over the forecast period due to reimbursement coverage and technological advancements in VADs.
• The VAD based on the site of implantation are categorized into Left Ventricular Assist Devices (LVAD) and Right Ventricular Assist Devices (RVAD). When the LVAD and RVAD are implanted together they are termed Biventricular Assist Devices (BIVAD).
• North America congestive heart failure treatment devices market dominated the global market with a 45.6% share in 2024, this can be attributed to the presence of a large population base suffering from CVDs coupled with a significant geriatric population base.
• The market participants are actively involved in the improvement of the current product portfolio, in order to sustain their market position. Additionally, drug development and their market entry in the untapped nations are expected to propel market growth.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Regional scope
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Congestive Heart Failure Treatment Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of cardiovascular diseases
    • 3.2.1.2. Technological advancements in heart failure treatment
    • 3.2.1.3. Growing awareness and early detection of heart failure
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of devices
    • 3.2.2.2. Complications and risks associated with device implantation
• 3.3. Congestive Heart Failure Treatment Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Congestive Heart Failure Treatment Devices Market: Product Estimates & Trend Analysis

• 4.1. Global Congestive Heart Failure Treatment Devices Market: Product Dashboard
• 4.2. Global Congestive Heart Failure Treatment Devices Market: Product Movement Analysis
• 4.3. Global Congestive Heart Failure Treatment Devices Market by Product, Revenue
• 4.4. Ventricular Assist Devices
  • 4.4.1. Ventricular assist devices market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. LVAD
    • 4.4.2.1. LVAD market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. RVAD
    • 4.4.3.1. RVAD market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. BiVAD
    • 4.4.4.1. BiVAD market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Counter Pulsation Devices
  • 4.5.1. Counter pulsation devices market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Implantable Cardioverter Defibrillators
  • 4.6.1. Implantable cardioverter defibrillators market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.2. Transvenous ICDs
    • 4.6.2.1. Transvenous ICDs market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.3. Subcutaneous ICDs
    • 4.6.3.1. Subcutaneous ICDs market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Pacemakers
  • 4.7.1. Pacemakers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.2. Implantable
    • 4.7.2.1. Implantable market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.3. External
    • 4.7.3.1. External market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Cardiac Resynchronization Therapy
  • 4.8.1. Cardiac resynchronization therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.2. Cardiac resynchronization therapy-defibrillators (CRT-D)
    • 4.8.2.1. Cardiac resynchronization therapy-defibrillators (CRT-D) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.3. Cardiac Resynchronization Therapy-Pacemakers (CRT-P)
    • 4.8.3.1. Cardiac Resynchronization Therapy-Pacemakers (CRT-P) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Congestive Heart Failure Treatment Devices Market: Regional Estimates & Trend Analysis by Product

• 5.1. Regional Dashboard
• 5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.3. North America
  • 5.3.1. U.S.
    • 5.3.1.1. Key country dynamics
    • 5.3.1.2. Regulatory framework/ reimbursement structure
    • 5.3.1.3. Competitive scenario
    • 5.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.2. Canada
    • 5.3.2.1. Key country dynamics
    • 5.3.2.2. Regulatory framework/ reimbursement structure
    • 5.3.2.3. Competitive scenario
    • 5.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.3. Mexico
    • 5.3.3.1. Key country dynamics
    • 5.3.3.2. Regulatory framework/ reimbursement structure
    • 5.3.3.3. Competitive scenario
    • 5.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 5.4. Europe
  • 5.4.1. UK
    • 5.4.1.1. Key country dynamics
    • 5.4.1.2. Regulatory framework/ reimbursement structure
    • 5.4.1.3. Competitive scenario
    • 5.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Germany
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Regulatory framework/ reimbursement structure
    • 5.4.2.3. Competitive scenario
    • 5.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. France
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Regulatory framework/ reimbursement structure
    • 5.4.3.3. Competitive scenario
    • 5.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Italy
    • 5.4.4.1. Key country dynamics
    • 5.4.4.2. Regulatory framework/ reimbursement structure
    • 5.4.4.3. Competitive scenario
    • 5.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Spain
    • 5.4.5.1. Key country dynamics
    • 5.4.5.2. Regulatory framework/ reimbursement structure
    • 5.4.5.3. Competitive scenario
    • 5.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.6. Norway
    • 5.4.6.1. Key country dynamics
    • 5.4.6.2. Regulatory framework/ reimbursement structure
    • 5.4.6.3. Competitive scenario
    • 5.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.7. Sweden
    • 5.4.7.1. Key country dynamics
    • 5.4.7.2. Regulatory framework/ reimbursement structure
    • 5.4.7.3. Competitive scenario
    • 5.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.8. Denmark
    • 5.4.8.1. Key country dynamics
    • 5.4.8.2. Regulatory framework/ reimbursement structure
    • 5.4.8.3. Competitive scenario
    • 5.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Asia Pacific
  • 5.5.1. Japan
    • 5.5.1.1. Key country dynamics
    • 5.5.1.2. Regulatory framework/ reimbursement structure
    • 5.5.1.3. Competitive scenario
    • 5.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. China
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework/ reimbursement structure
    • 5.5.2.3. Competitive scenario
    • 5.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. India
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Regulatory framework/ reimbursement structure
    • 5.5.3.3. Competitive scenario
    • 5.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.4. Australia
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Regulatory framework/ reimbursement structure
    • 5.5.4.3. Competitive scenario
    • 5.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.5. South Korea
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Regulatory framework/ reimbursement structure
    • 5.5.5.3. Competitive scenario
    • 5.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.6. Thailand
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Regulatory framework/ reimbursement structure
    • 5.5.6.3. Competitive scenario
    • 5.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Latin America
  • 5.6.1. Brazil
    • 5.6.1.1. Key country dynamics
    • 5.6.1.2. Regulatory framework/ reimbursement structure
    • 5.6.1.3. Competitive scenario
    • 5.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Argentina
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Regulatory framework/ reimbursement structure
    • 5.6.2.3. Competitive scenario
    • 5.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. MEA
  • 5.7.1. South Africa
    • 5.7.1.1. Key country dynamics
    • 5.7.1.2. Regulatory framework/ reimbursement structure
    • 5.7.1.3. Competitive scenario
    • 5.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.2. Saudi Arabia
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Regulatory framework/ reimbursement structure
    • 5.7.2.3. Competitive scenario
    • 5.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.3. UAE
    • 5.7.3.1. Key country dynamics
    • 5.7.3.2. Regulatory framework/ reimbursement structure
    • 5.7.3.3. Competitive scenario
    • 5.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.4. Kuwait
    • 5.7.4.1. Key country dynamics
    • 5.7.4.2. Regulatory framework/ reimbursement structure
    • 5.7.4.3. Competitive scenario
    • 5.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Company/Competition Categorization
• 6.2. Vendor Landscape
  • 6.2.1. Key company market share analysis, 2024
  • 6.2.2. Jarvik Heart Inc.
    • 6.2.2.1. Company overview
    • 6.2.2.2. Financial performance
    • 6.2.2.3. Product benchmarking
    • 6.2.2.4. Strategic initiatives
  • 6.2.3. ReliantHeart, Inc.
    • 6.2.3.1. Company overview
    • 6.2.3.2. Financial performance
    • 6.2.3.3. Product benchmarking
    • 6.2.3.4. Strategic initiatives
  • 6.2.4. Biotronik SE & Co. KG
    • 6.2.4.1. Company overview
    • 6.2.4.2. Financial performance
    • 6.2.4.3. Product benchmarking
    • 6.2.4.4. Strategic initiatives
  • 6.2.5. Berlin Heart GmbH
    • 6.2.5.1. Company overview
    • 6.2.5.2. Financial performance
    • 6.2.5.3. Product benchmarking
    • 6.2.5.4. Strategic initiatives
  • 6.2.6. Abbott
    • 6.2.6.1. Company overview
    • 6.2.6.2. Financial performance
    • 6.2.6.3. Product benchmarking
    • 6.2.6.4. Strategic initiatives
  • 6.2.7. Medtronic
    • 6.2.7.1. Company overview
    • 6.2.7.2. Financial performance
    • 6.2.7.3. Product benchmarking
    • 6.2.7.4. Strategic initiatives
  • 6.2.8. Boston Scientific Corporation
    • 6.2.8.1. Company overview
    • 6.2.8.2. Financial performance
    • 6.2.8.3. Product benchmarking
    • 6.2.8.4. Strategic initiatives
  • 6.2.9. Teleflex, Inc.
    • 6.2.9.1. Company overview
    • 6.2.9.2. Financial performance
    • 6.2.9.3. Product benchmarking
    • 6.2.9.4. Strategic initiatives

관련자료